High-Level Overview
Francis Medical is a medical device company developing the Vanquish® Water Vapor Ablation System, a minimally invasive therapy for treating localized intermediate-risk prostate cancer using thermal energy from sterile water vapor.[1][2][3] The system targets cancerous prostate tissue via a simple transurethral outpatient procedure, aiming to ablate tumors while minimizing side effects like urinary incontinence and erectile dysfunction common in traditional treatments such as surgery or radiation.[1][2][3] It serves patients with low-to-intermediate risk prostate cancer, offering an alternative to active surveillance or aggressive interventions, with plans to expand to bladder and kidney cancers.[1][2] The company achieved FDA 510(k) clearance on December 2, 2025, for prostate tissue ablation, supported by promising early data from the VAPOR 2 multi-center pivotal study (n=235), where 12-month results on the first 110 patients showed positive outcomes in cancer management and patient satisfaction.[3][7]
Growth momentum includes a $18 million Series A funding round in December 2018 led by Arboretum Ventures, with participation from H2Oey Ventures, Tonkawa, and Boston Scientific, fueling development and clinical trials.[4] Post-clearance, Francis Medical is pursuing international approvals and long-term VAPOR 2 follow-up through five years to solidify its role as a first-line therapy.[1][3]
Origin Story
Francis Medical was formed in May 2018 in Minneapolis, Minnesota, as a tribute to founder Michael Hoey's father, Francis Hoey, who died from prostate cancer after enduring harsh side effects from conventional treatments.[1][4] Michael Hoey, a serial inventor and entrepreneur serving as chief technology officer, pioneered water vapor thermal ablation technology; his prior company, NxThera, was acquired by Boston Scientific for $306 million upfront plus up to $100 million in milestones.[4] The idea emerged from Hoey's success with water vapor for benign prostatic hyperplasia (BPH)—notably Boston Scientific's 2018 acquisition of Rezum—repurposed for cancerous urological conditions starting with prostate cancer.[1][4]
Early traction came swiftly with the $18 million Series A launch, enabling clinical advancement.[4] Key milestones include the VAPOR 2 study's completion of enrollment and publication of 12-month data in 2025, alongside FDA clearance in December 2025.[3][7] Dr. Christopher Dixon, Chief Medical Officer, has championed the technology's potential to balance cancer control with quality of life.[1]
Core Differentiators
- Targeted, Minimally Invasive Mechanism: The Vanquish System delivers precise thermal energy via sterile water vapor through a transurethral procedure, respecting the prostate's natural boundaries to ablate cancer tissue without damaging surrounding structures like the urethra or nerves—unlike radical prostatectomy or radiation.[1][2][3][6]
- Reduced Side Effects: Designed to avoid long-term complications (e.g., incontinence, erectile dysfunction) plaguing traditional therapies, offering a quality-of-life-preserving option for localized prostate cancer.[1][2][3][4]
- Clinical Validation: Backed by VAPOR 2 pivotal study data (n=235, with 12-month results on n=110 showing efficacy), plus peer-reviewed publications like the 2025 *Research and Reports in Urology* study on transurethral water vapor ablation for intermediate-risk prostate cancer.[3][7]
- Scalability and Expansion: Built on proven water vapor tech, with roadmap for bladder/kidney applications and global regulatory pursuits post-2025 U.S. clearance.[1][2]
Role in the Broader Tech Landscape
Francis Medical rides the wave of advancing prostate cancer diagnostics—improved imaging, biopsies, and patient advocacy—enabling focal therapies over whole-gland treatments for the one-in-eight men facing this disease.[2][3] Timing aligns with demand for tissue-preserving options amid rising intermediate-risk diagnoses, where active surveillance risks progression and aggressive therapies impair function.[1][2] Market forces favor it: FDA clearance unlocks U.S. commercialization in a sector dominated by high-side-effect incumbents, while clinical data positions water vapor as a potential standard.[3][7]
The company influences medtech by validating convective water vapor ablation, inspiring extensions to other urological cancers and minimally invasive oncology trends, potentially disrupting surveillance-to-treatment pathways.[1][4][6]
Quick Take & Future Outlook
With fresh FDA clearance, Francis Medical is poised for commercial launch, leveraging VAPOR 2's ongoing five-year data to drive adoption as a go-to therapy for intermediate-risk prostate cancer.[3][7] Next steps include international expansions and pipeline growth into bladder/kidney indications, fueled by its investor-backed foundation.[1][4] Trends like precision oncology, AI-enhanced imaging, and value-based care will amplify its trajectory, evolving it from prostate pioneer to urological cancer leader—delivering on its promise to be tough on cancer, gentle on patients.[1][2]
